Detalhe da pesquisa
1.
Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
Drug Metab Dispos
; 49(10): 870-881, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34321251
2.
Late-stage optimization of a tercyclic class of S1P3-sparing, S1P1 receptor agonists.
Bioorg Med Chem Lett
; 26(2): 466-471, 2016 Jan 15.
Artigo
Inglês
| MEDLINE | ID: mdl-26687487
3.
Piperazinyl-oxadiazoles as selective sphingosine-1-phosphate receptor agonists.
Bioorg Med Chem Lett
; 24(20): 4807-11, 2014 Oct 15.
Artigo
Inglês
| MEDLINE | ID: mdl-25241927
4.
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
ACS Med Chem Lett
; 9(4): 300-305, 2018 Apr 12.
Artigo
Inglês
| MEDLINE | ID: mdl-29670690
5.
An Asymmetric Route to Novel Chiral Cyclohexenones with Spiro-Connected Cyclopentenes. Further Utility of Chiral Bicyclic Thiolactams and the [3,3] Thio-Claisen Products.
J Org Chem
; 64(10): 3585-3591, 1999 May 14.
Artigo
Inglês
| MEDLINE | ID: mdl-11674485